Literature DB >> 30340934

Sustained Neonatal Inflammation Is Associated with Poor Growth in Infants Born Very Preterm during the First Year of Life.

Eduardo Cuestas1, Belén Aguilera2, Manuel Cerutti2, Alina Rizzotti3.   

Abstract

OBJECTIVE: To determine whether a sustained neonatal systemic inflammatory response was associated with poor postnatal growth among infants born very preterm during the first year of life. STUDY
DESIGN: We studied prospectively 192 infants born preterm (birth weight ≤1.5 kg and gestational age ≤31 weeks). Weight, length, and head circumference were measured at birth, term, 4, and 12 months of corrected age. Serial C-reactive protein and procalcitonin were measured at 1, 3, 7, 14, and 28 days of age and averaged for each infant. A sustained neonatal systemic inflammatory response was defined as an average C-reactive protein level greater than the median for the group. Analysis was undertaken with linear mixed models.
RESULTS: Decreases in mean z scores for weight, length, and head circumference were associated with the presence of a sustained neonatal systemic inflammatory response from birth to 12 months of corrected age (β [95% CI] = -0.282 [-0.306 to -0.258]; -1.899 [-2.028,-1.769]; -0.806 [-0.910, to -0.701], P < .001, respectively) in main effect models. This association remained significant after including interaction terms for bronchopulmonary dysplasia, neonatal sepsis, and necrotizing enterocolitis (β [95% CI] = -0.393 [-0.520 to -0.265]; -2.128 [-2.754, -1.503]; -1.102 [-1.604, -0.600]; P < .001; respectively) in interaction models.
CONCLUSIONS: A sustained neonatal systemic inflammatory response was associated with poor postnatal growth, particularly poor linear growth. Serial C-reactive protein and procalcitonin may be useful markers for identifying infants at risk for postnatal growth failure.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  C reactive protein; procalcitonin

Mesh:

Substances:

Year:  2018        PMID: 30340934     DOI: 10.1016/j.jpeds.2018.09.032

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Systemic Inflammation in the First 2 Weeks after Birth as a Determinant of Physical Growth Outcomes in Hospitalized Infants with Extremely Low Gestational Age.

Authors:  Mandy B Belfort; Sara E Ramel; Camilia R Martin; Raina Fichorova; Karl C K Kuban; Timothy Heeren; Rebecca C Fry; T Michael O'Shea
Journal:  J Pediatr       Date:  2021-09-08       Impact factor: 4.406

2.  Length of Nutritional Transition Associates Negatively with Postnatal Growth in Very Low Birthweight Infants.

Authors:  Lotta Immeli; Ulla Sankilampi; Pauliina M Mäkelä; Markus Leskinen; Reijo Sund; Sture Andersson; Päivi Luukkainen
Journal:  Nutrients       Date:  2021-11-06       Impact factor: 5.717

3.  Preterm infant meconium microbiota transplant induces growth failure, inflammatory activation, and metabolic disturbances in germ-free mice.

Authors:  Henni Hiltunen; Hila Hanani; Raakel Luoto; Sondra Turjeman; Oren Ziv; Erika Isolauri; Seppo Salminen; Omry Koren; Samuli Rautava
Journal:  Cell Rep Med       Date:  2021-11-16

4.  Nutrition Support Practices for Infants Born &lt;750 Grams or &lt;25 Weeks Gestation: A Call for More Research.

Authors:  Melissa Thoene; Ann Anderson-Berry
Journal:  Int J Environ Res Public Health       Date:  2022-09-02       Impact factor: 4.614

5.  Intestinal Dysbiosis and the Developing Lung: The Role of Toll-Like Receptor 4 in the Gut-Lung Axis.

Authors:  Stephen Wedgwood; Kimberly Gerard; Katrina Halloran; Ashley Hanhauser; Sveva Monacelli; Cris Warford; Phung N Thai; Nipavan Chiamvimonvat; Satyan Lakshminrusimha; Robin H Steinhorn; Mark A Underwood
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

6.  Impaired functional capacity of polarised neonatal macrophages.

Authors:  Stephan Dreschers; Kim Ohl; Nora Schulte; Klaus Tenbrock; Thorsten W Orlikowsky
Journal:  Sci Rep       Date:  2020-01-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.